{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:04:08Z","timestamp":1779789848786,"version":"3.53.1"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015758","name":"Novo Nordisk Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp;amp; Metabol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the oral semaglutide use among Mexican adults with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PIONEER REAL was a multinational, open\u2010label study evaluating oral semaglutide in patients without prior injectable glucose\u2010lowering treatment. This analysis focuses on data from Mexico.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 177 patients, 139 (78.5%) completed the study and 111 (62.7%) remained on treatment at the end. The mean (SD) age was 54.0 (10.96) years, 57.6% were women, 59.3% had obesity, and 44.6% had a medical history of cardiovascular disease. The average T2D duration was 5.7\u2009years (SD 6.45), with mean HbA1c at 8.1% (SD 1.85). At week 38, mean HbA1c had decreased to 6.8% (estimated mean [SE] change in HbA1c, \u22121.3% [0.11];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and body weight had decreased from 87.8\u2009kg (19.34) to 85.3\u2009kg (estimated mean [SE] change in body weight, \u22124.3\u2009kg [0.56];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), as had waist circumference (estimated mean [SE] change, \u22123.7\u2009cm [0.54];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Additionally, satisfaction with treatment increased over time. Only 6.2% of patients had adverse events leading to withdrawal of semaglutide.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>According to this real\u2010world study, starting oral semaglutide treatment in Mexico is associated with notable decreases in both HbA1c levels and body weight among patients with type 2 diabetes. Satisfaction with treatment also improved significantly. Moreover, the safety profile is consistent with that of previous studies.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      registration NCT04601753.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/edm2.70219","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:10:50Z","timestamp":1776312650000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multicentre, Prospective, Non\u2010Interventional Single\u2010Arm Study Investigating the Impact of Once\u2010Daily Oral Semaglutide in a Real\u2010World Adult Population With Type 2 Diabetes in Mexico"],"prefix":"10.1002","volume":"9","author":[{"given":"Guillermo","family":"Gonz\u00e1lez\u2010G\u00e1lvez","sequence":"first","affiliation":[{"name":"Instituto Jalisciense de Investigaci\u00f3n en Diabetes y Obesidad  Guadalajara Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Garnica\u2010Cuellar","sequence":"additional","affiliation":[{"name":"Endocrinology Division Centro M\u00e9dico Nacional 20 de Noviembre, Institute for Social Security and Services for State  Mexico City Mexico"},{"name":"Diabetes and Obesity Workgroup Sociedad Mexicana de Nutrici\u00f3n y Endocrinolog\u00eda  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Col\u00edn\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"Colegio Mexicano de Obesidad y Nutrici\u00f3n A.C. Jos\u00e9 Mar\u00eda Rico  Mexico City Mexico"},{"name":"Hospital \u00c1ngeles Santa M\u00f3nica  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5159-9856","authenticated-orcid":false,"given":"Aldo","family":"Ferreira\u2010Hermosillo","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Enfermedades Endocrinas, Centro M\u00e9dico Nacional Siglo XXI, IMSS  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia A.","family":"Jim\u00e9nez\u2010Ramos","sequence":"additional","affiliation":[{"name":"CICEJ Centro de Investigaci\u00f3n Cl\u00ednica Endocrinol\u00f3gica de Jalisco  Guadalajara Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleida Y.","family":"Contreras\u2010Sandoval","sequence":"additional","affiliation":[{"name":"Novo Nordisk Mexico  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cruz\u2010Puente","sequence":"additional","affiliation":[{"name":"Novo Nordisk Mexico  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Duarte\u2010Vega","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Medicina Interna, Hospital Civil Juan I. Menchaca  Guadalajara Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuw030"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-9-3"},{"key":"e_1_2_13_4_1","unstructured":"International Diabetes Federation \u201cIDF Diabetes Atlas 10th Edition 2021 \u201d(2021) https:\/\/diabetesatlas.org\/idfawp\/resource\u2010files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2083"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1901642"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01668-6"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01413-5"},{"issue":"1","key":"e_1_2_13_19_1","first-page":"57","article-title":"Diabetes Treatment Satisfaction Questionnaire (DTSQ) of in Non\u2010Ambulatory Type 2 Diabetic Patients","volume":"108","author":"Baccaro F.","year":"2016","journal-title":"Bolet\u00edn de la Asociaci\u00f3n M\u00e9dica de Puerto Rico"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0245-x"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0199-z"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12285"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605368"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108927"},{"issue":"6","key":"e_1_2_13_25_1","first-page":"474","article-title":"Type 2 Diabetes Epidemic in Mexico. Burden of Disease 1990\u20102021 Analysis and Implications for Public Policies","volume":"159","author":"Montoya A.","year":"2023","journal-title":"Gaceta M\u00e9dica de Mexico"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2023.10.038"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2276"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.21149\/12842"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14453"},{"issue":"12","key":"e_1_2_13_30_1","article-title":"A Comprehensive Review of the Role of GLP\u20101 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure","volume":"16","author":"Gul U.","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1376115"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2025.01.056"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70219","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/edm2.70219","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.70219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:19:29Z","timestamp":1779787169000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.70219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/edm2.70219"],"URL":"https:\/\/doi.org\/10.1002\/edm2.70219","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2026-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70219"}}